George C Prendergast
George C Prendergast
Professor, President & CEO, Lankenau Institute for Medical Research
Verified email at - Homepage
Cited by
Cited by
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller, JB DuHadaway, PS Donover, E Sutanto-Ward, GC Prendergast
Nature medicine 11 (3), 312-319, 2005
Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain
AR Ferré-D'Amaré, GC Prendergast, EB Ziff, SK Burley
Nature 363 (6424), 38-45, 1993
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
DE Jensen, M Proctor, ST Marquis, HP Gardner, SI Ha, LA Chodosh, ...
Oncogene 16 (9), 1097-1112, 1998
Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region
GC Prendergast, EB Ziff
Science 251 (4990), 186-189, 1991
Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation
GC Prendergast, D Lawe, EB Ziff
Cell 65 (3), 395-407, 1991
Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
DY Hou, AJ Muller, MD Sharma, J DuHadaway, T Banerjee, M Johnson, ...
Cancer research 67 (2), 792-801, 2007
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
A Bessede, M Gargaro, MT Pallotta, D Matino, G Servillo, C Brunacci, ...
Nature 511 (7508), 184-190, 2014
Mechanisms of apoptosis by c-Myc
GC Prendergast
Oncogene 18 (19), 2967-2987, 1999
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan
R Metz, JB DuHadaway, U Kamasani, L Laury-Kleintop, AJ Muller, ...
Cancer research 67 (15), 7082-7087, 2007
Classification of current anticancer immunotherapies
L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ...
Oncotarget 5 (24), 12472, 2014
Indoleamine 2, 3‐dioxygenase in T‐cell tolerance and tumoral immune escape
JB Katz, AJ Muller, GC Prendergast
Immunological reviews 222 (1), 206-221, 2008
Discovery of IDO1 inhibitors: from bench to bedside
GC Prendergast, WP Malachowski, JB DuHadaway, AJ Muller
Cancer research 77 (24), 6795-6811, 2017
Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
GC Prendergast, C Smith, S Thomas, L Mandik-Nayak, L Laury-Kleintop, ...
Cancer immunology, immunotherapy 63, 721-735, 2014
Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models
N Takahashi, L Duprez, S Grootjans, A Cauwels, W Nerinckx, ...
Cell death & disease 3 (11), e437-e437, 2012
The polyproline region of p53 is required to activate apoptosis but not growth arrest
D Sakamuro, P Sabbatini, E White, GC Prendergast
Oncogene 15 (8), 887-898, 1997
BIN1 is a novel MYC–interacting protein with features of a tumour suppressor
D Sakamuro, KJ Elliott, R Wechsler-Reya, GC Prendergast
Nature genetics 14 (1), 69-77, 1996
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.
P Carmeliet, L Kieckens, L Schoonjans, B Ream, A Van Nuffelen, ...
The Journal of clinical investigation 92 (6), 2746-2755, 1993
Immune escape as a fundamental trait of cancer: focus on IDO
GC Prendergast
Oncogene 27 (28), 3889-3900, 2008
c‐Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II.
LH Li, C Nerlov, G Prendergast, D MacGregor, EB Ziff
The EMBO journal 13 (17), 4070-4079, 1994
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
R Metz, S Rust, JB DuHadaway, MR Mautino, DH Munn, NN Vahanian, ...
Oncoimmunology 1 (9), 1460-1468, 2012
The system can't perform the operation now. Try again later.
Articles 1–20